Endometrial Cancer

P=N/A, N=74, Completed, Rajavithi Hospital | Recruiting --> Completed

Via the analysis of longer homopolymer repeat regions, the Promega LMR MSI assay demonstrates enhanced sensitivity for subtle phenotypes. This assay may be better suited than other PCR- and CE-based approaches for certain disease types.

Both assays showed comparable sensitivity in establishing MSI status for CRC and the expanded spectrum of non-CRC tumors. Advantages such as increased number of LMR loci in the Promega assay and the need for only tumor specimen in the Idylla assay increase the utility of these assays in determination of MSI status in a variety of cancers.

The TruSight Oncology 500 comprehensive solid tumor next-generation sequencing panel with HRD assay demonstrated a high degree of sensitivity and specificity for deployment in a clinical setting.

The research study demonstrated the effectiveness of the Promega OncoMate MSI Dx Analysis System in detecting MSI in colorectal cancer, endometrial cancer, and sebaceous neoplasms in comparison with MMR IHC. The correlation for CRC was excellent, and EC and SN showed good correlation, though further investigation into discordant samples is necessary. This research study indicates that the OncoMate MSI Dx test offers excellent clinical utility in the diagnosis and management of LS in CRC, and can provide additional insights into EC and SN sample MSI status for LS and MTS research.

P1, N=572, Recruiting, Seagen Inc. | N=430 --> 572 | Trial completion date: Jan 2027 --> Nov 2027 | Trial primary completion date: Jun 2025 --> Nov 2027

P1/2, N=250, Recruiting, Daiichi Sankyo | Trial primary completion date: Dec 2024 --> Dec 2025

P1, N=141, Recruiting, GlaxoSmithKline | Trial completion date: Oct 2026 --> Sep 2028

P1, N=50, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2024 --> Oct 2025

P2, N=62, Recruiting, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Recruiting | N=31 --> 62 | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Feb 2025 --> Feb 2026

P=N/A, N=120, Not yet recruiting, Beijing Chaoyang Hospital, Capital Medical University; Beijing Chaoyang Hospital, Capital Medical University

P=N/A, N=440, Not yet recruiting, Guangdong Second Provincial General Hospital; MSD Holding Co., LTD

P=N/A, N=30, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center

P=N/A, N=0, Recruiting, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine; Shanghai First Maternity and Infant Hospital, Tongji University Sc

P1, N=474, Not yet recruiting, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center

P1, N=40, Completed, Hebei General Hospital; Hebei General Hospital

P1, N=25, Not yet recruiting, Cancer Hospital Chinese Academy of Medical Sciences Union Medical College; Cancer Hospital Chinese Academy of Medical Sciences

P1, N=92, Not yet recruiting, Jilin Cancer Hospital; Jilin Cancer Hospital

P1, N=197, Not yet recruiting, Astellas Pharma Global Development, Inc.

P2, N=18, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Aug 2028 --> May 2027 | Trial primary completion date: Aug 2025 --> Jun 2024

P=N/A, N=15, Completed, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Tamoxifen is the drug of choice in ER-positive breast cancer, and several studies have shown better disease-free survival in these patients...In addition, a computational approach involving molecular modeling and simulation of phosphorylated and unphosphorylated forms of PAK1 was used to elucidate the dynamics of nuclear localization. Thus, PAK1 phosphorylation by JAK2 is a prerequisite for its nuclear localization and its tumorigenic effects on endometrial cancer cells.

P2, N=130, Active, not recruiting, Dana-Farber Cancer Institute | Recruiting --> Active, not recruiting | Trial completion date: Aug 2029 --> Aug 2030 | Trial primary completion date: Aug 2026 --> Aug 2027

P1, N=87, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Jun 2026

No abstract available

ET/HT can probably be used after ovarian neoplasms except for granulosa cell tumors, and with great caution after low-grade serous ovarian carcinoma and serous borderline ovarian tumors. ET/HT can be used with great caution in women after estrogen receptor (ER)/progesterone receptor (PR)-positive breast cancer and is probably allowed after ER/PR-negative breast cancer.

These findings suggest that inhibiting NEDD4 reduces ESC growth and invasion in EM by regulating PTGS2-dependent ferroptosis.

TROAP is transcriptionally activated by E2F1 and promotes EC progression by enhancing cell proliferation, metastasis, and glycolysis. The E2F1-TROAP axis may serve as a potential therapeutic target for EC treatment.

P=N/A, N=1000, Recruiting, M.D. Anderson Cancer Center | N=50 --> 1000 | Trial completion date: Jun 2024 --> Jun 2028 | Trial primary completion date: Jun 2024 --> Jun 2028

Our panel can classify ECs into four subgroups through a simplified process and can be implemented reflexively in clinical practice.

KRAS-mut represents a genotypically distinct group of ECs. Overlap exists with genomic predictors (TMB-high, MSI-high) of immunotherapy response, suggesting a possible biomarker-driven combination option with immunotherapy. Clinical trials to evaluate these strategies should be developed.

In vivo experiments in mouse models and in vitro studies in human cell lines demonstrate that downregulation of HOXA10 leads to endometrial epithelial cell proliferation, failure of stromal cell decidualization, altered expression of genes involved in cell cycle regulation, immunomodulation, and various signaling pathways. These disruptions are speculated to cause infertility associated with the disorders of the endometrium.

Key stakeholders came together including basic scientists, clinical investigators, and patient advocates to identify critical research gaps that, when addressed, would facilitate more comprehensive and rapid progress in understanding and ultimately treating USC across all patients. NCI released a supplemental funding opportunity (NOT-CA-24-044) in Spring 2024 to facilitate rapid translation of these recommendations.

This was the first study to investigate the frequency of carriers of MUTYH-associated polyposis in East Asians, including specific subgroups, utilizing gnomAD and a Korean genome database. Our data provide valuable reference information for future investigations of MUTYH-associated polyposis to understand the genetic diversity and specific variants associated with this condition in East Asian populations.

P1, N=100, Active, not recruiting, Lyell Immunopharma, Inc. | Recruiting --> Active, not recruiting

P2, N=40, Not yet recruiting, Faeth Therapeutics | N=120 --> 40 | Initiation date: Sep 2024 --> Dec 2024

P=N/A, N=200, Active, not recruiting, University College Cork | Trial completion date: Jun 2024 --> Dec 2024

Additionally, pathway enrichment suggested that NUMB is involved in the Wnt pathway. This study highlights the predictive role of CTNNB1 across cancers, suggesting that CTNNB1 might serve as a potential biomarker for the diagnosis and prognosis evaluation of various malignant tumors.

EC can be divided into two immune subtypes based on immunogenes. Low expression of S100A9 and high expression of IL2RB, HLA-DRB1, CD3E, and CD3D suggest sensitivity to immunotherapy and a good prognosis.

Conclusion The downregulation of E-cadherin is likely due to disruptions in the cadherin-catenin complex, which is linked to the potential for local and distant metastasis in cancer. This study underscores the significance of cell adhesion molecule expression in predicting the prognosis of EC.

A 65-year-old woman with a past medical history of hyperlipidemia on atorvastatin for four years, type 2 diabetes, sciatica, and a prior history of endometrial cancer, presented to the emergency department due to proximal muscle weakness worsening over 2-3 months...During her hospital course, she was started on prednisone, fluids, and intravenous immunoglobulin (IVIG). Once completing two days of IVIG, the patient was discharged to rehab with rheumatology follow-up. The purpose of this case is to elucidate a rare side effect of a medication despite being on it for several years and to increase awareness and attention to an adverse effect that may one day lead to stratifying patients' risk on the medication.

P1, N=15, Recruiting, EtiraRx Australia Pty Ltd | Not yet recruiting --> Recruiting